Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Illumina    ILMN

ILLUMINA (ILMN)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Insider Trading Activity Illumina, Inc. (NASDAQ:ILMN) – Director Sold 15,000 shares of Stock

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/21/2017 | 04:49am CEST

Insider Trading Activity For Illumina, Inc. (NASDAQ:ILMN)

Jay T Flatley , Director of Illumina, Inc. (NASDAQ:ILMN) reportedly Sold 15,000 shares of the company’s stock at an average price of 170.77 for a total transaction amount of $2,561,550.00 SEC Form

Insider Trading History For Illumina, Inc. (NASDAQ:ILMN)

  • On 11/8/2012 Jay T Flatley, CEO, sold 5,000 with an average share price of $47.99 per share and the total transaction amounting to $239,950.00.View SEC Filing
  • On 3/11/2013 Marc Stapley, CFO, sold 4,468 with an average share price of $53.71 per share and the total transaction amounting to $239,976.28.View SEC Filing
  • On 4/8/2013 William H Rastetter, Director, sold 20,000 with an average share price of $54.95 per share and the total transaction amounting to $1,099,000.00.View SEC Filing
  • On 4/8/2013 Marc Stapley, CFO, sold 9,175 with an average share price of $55.00 per share and the total transaction amounting to $504,625.00.View SEC Filing
  • On 4/8/2013 Christian Cabou, SVP, sold 16,500 with an average share price of $55.00 per share and the total transaction amounting to $907,500.00.View SEC Filing
  • On 5/7/2013 Tristan Orpin, SVP, sold 5,000 with an average share price of $65.68 per share and the total transaction amounting to $328,400.00.View SEC Filing
  • On 5/9/2013 Jay T Flatley, CEO, sold 20,000 with an average share price of $66.63 per share and the total transaction amounting to $1,332,600.00.View SEC Filing
  • Analyst Ratings For Illumina, Inc. (NASDAQ:ILMN)
    These are 3 Sell Ratings, 9 Hold Ratings, 8 Buy Ratings .
    The current consensus rating for Illumina, Inc. (NASDAQ:ILMN) is Hold (Score: 2.25) with a consensus target price of $162.42 , a potential (5.56% downside)

    Analyst Ratings History For Illumina, Inc. (NASDAQ:ILMN)

    • On 10/8/2015 William Blair Reiterated Rating Buy
    • On 10/21/2015 Wedbush Boost Price Target of rating Outperform with a price target of $150.00 to $160.00 with a price target of $141.00
    • On 4/22/2016 Avondale Partners Reiterated Rating Market Perform with a price target of $175.00 to $160.00
    • On 5/3/2016 Nomura Lower Price Target of rating Buy with a price target of $210.00 to $180.00
    • On 5/4/2016 Stifel Nicolaus Reiterated Rating Buy with a price target of $215.00 to $160.00
    • On 7/27/2016 Mizuho Boost Price Target of rating Neutral with a price target of $138.00 to $148.00

    Recent Trading Activity for Illumina, Inc. (NASDAQ:ILMN)
    Shares of Illumina, Inc. closed the previous trading session at 171.97 down -1.91 -1.10% with 653,969 shares trading hands.

    The post Insider Trading Activity Illumina, Inc. (NASDAQ:ILMN) – Director Sold 15,000 shares of Stock appeared first on Market Exclusive.

    © Market Exclusive 2017, source Market Exclusive

    share with twitter share with LinkedIn share with facebook
    share via e-mail
    0
    Latest news on ILLUMINA
    07/21 INSIDER TRADING ACTIVITY ILLUMINA, I : ILMN) – Director Sold 15,000 shares..
    07/20 ILLUMINA : Patent Issued for Nucleic Acid Sample Enrichment for Sequencing Appli..
    07/20 ILLUMINA : Combine Solicitation - Illumina reagents
    07/19 ILLUMINA : $459,954 Federal Contract Awarded to Illumina
    07/12 ILLUMINA : Combine Solicitation - Illumina Miseq PM
    07/11 ILLUMINA : to Announce Second Quarter 2017 Financial Results on Tuesday, August ..
    07/06 ILLUMINA : Announces FDA-approved Next-Generation Sequencing Cancer Companion Di..
    07/06 ILLUMINA : Genomics England Adopts Illumina's BaseSpace Variant Interpreter for ..
    06/29 ILLUMINA : Announces FDA-approved Next-Generation Sequencing Cancer Companion Di..
    06/27 SPECIAL NOTICE - NOTICE OF INTENT TO : Illumina Reagents compatible with Illumin..
    More news
    News from SeekingAlpha
    07/10 BRUNCH, CRAFT BEER, AND INVESTING : A Millennial's Portfolio
    06/30 Illumina updates on cancer companion diagnostic test kit
    06/27 If You Like Illumina, You'll Love Genomic Health
    06/22 PacBio Not Back To Square One But Definitely Back To A 'Show Me' Story
    06/04 WEEK IN REVIEW : Hong Kong's Cirina Merges With GRAIL For Early Stage Cancer Dia..
    Financials ($)
    Sales 2017 2 655 M
    EBIT 2017 674 M
    Net income 2017 682 M
    Finance 2017 862 M
    Yield 2017 -
    P/E ratio 2017 34,74
    P/E ratio 2018 43,47
    EV / Sales 2017 9,26x
    EV / Sales 2018 8,07x
    Capitalization 25 434 M
    Chart ILLUMINA
    Duration : Period :
    Illumina Technical Analysis Chart | ILMN | US4523271090 | 4-Traders
    Technical analysis trends ILLUMINA
    Short TermMid-TermLong Term
    TrendsBearishNeutralBullish
    Income Statement Evolution
    Consensus
    Sell
    Buy
    Mean consensus OUTPERFORM
    Number of Analysts 18
    Average target price 178 $
    Spread / Average Target 2,7%
    EPS Revisions
    Managers
    NameTitle
    Francis A. deSouza President, Chief Executive Officer & Director
    Jay T. Flatley Executive Chairman
    Sam A. Samad Chief Financial Officer & Senior Vice President
    Mostafa Ronaghi Chief Technology Officer & Senior Vice President
    Norman Fjeldheim Chief Information Officer
    Sector and Competitors
    1st jan.Capitalization (M$)
    ILLUMINA35.78%25 434
    THERMO FISHER SCIENTIFIC INC.27.66%70 470
    DANAHER5.33%56 958
    BOSTON SCIENTIFIC CORPORATION27.69%37 768
    ROYAL PHILIPS12.59%35 744
    INTUITIVE SURGICAL49.00%35 105